X

Clinical Trials

Contact Us

ECOG-ACRIN EA6141 (NCT02339571) – Accrual suspended effective 6/23/17

Study Number: ECOG-ACRIN EA6141 (NCT02339571) – Accrual suspended effective 6/23/17

This randomized phase II/III trial studies the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and nivolumab, may kill tumor cells by blocking blood flow to the tumor, by stimulating white blood cells to kill the tumor cells, or by attacking specific tumor cells and stop them from growing or kill them. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.

Please Note:

Accrual suspended effective 6/23/17

Contact Person(s)
  • Laura O’Brien, 314-996-5868

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.